Systematic Review and Meta-analysis

Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease

Diana E. Yung, Nir Horesh, Amy Lightner, Shomron Ben-Horin, Rami Eliakim, Anastasios Koulaouzidis, Uri Kopylov

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Several studies have reported the surgical outcomes of inflammatory bowel disease (IBD) patients exposed to vedolizumab (VDZ) preoperatively, with conflicting results. This meta-analysis aims to evaluate the risk of postoperative complications in IBD patients preoperatively exposed to VDZ in comparison with patients exposed to anti-tumor necrosis factor (anti-TNF) treatment or no biologic therapy.

Methods: A systematic review with a meta-analysis of the existing literature was conducted. The main outcomes included the odds of developing overall postoperative complications, infectious complications, surgical site infections, need for repeat surgery, and major postoperative complications, as defined by the Clavien-Dindo criteria.

Results: Four studies were included in the meta-analysis. The risk of all postoperative complications was not significantly different between IBD patients exposed preoperatively to VDZ vs anti-TNFs (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.21-1.88). In patients with ulcerative colitis (UC), the OR for complications was significantly lower in VDZ-exposed as opposed to anti-TNF-exposed patients (OR, 0.35; 95% CI, 0.14-0.85); the comparison was insignificant in Crohn's disease. There were no significant differences in the risk of infectious complications, surgical site infections, need for reoperation, or major surgical complications in patients exposed to VDZ vs anti-TNFs. There were no significant differences in outcomes when comparing patients exposed to VDZ with those not given biologic therapy.

Conclusions: This meta-analysis did not detect an increased risk of postoperative complications with preoperative VDZ exposure; the risk of overall complications may be lower in UC patients in comparison with those with anti-TNF exposure. These results merit further verification in future studies.

Original languageEnglish (US)
Pages (from-to)2327-2338
Number of pages12
JournalInflammatory Bowel Diseases
Volume24
Issue number11
DOIs
StatePublished - Oct 12 2018

Fingerprint

Inflammatory Bowel Diseases
Meta-Analysis
Surgical Wound Infection
Biological Therapy
Tumor Necrosis Factor-alpha
Odds Ratio
Reoperation
Ulcerative Colitis
Confidence Intervals
vedolizumab
Crohn Disease

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Yung, D. E., Horesh, N., Lightner, A., Ben-Horin, S., Eliakim, R., Koulaouzidis, A., & Kopylov, U. (2018). Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 24(11), 2327-2338. https://doi.org/10.1093/ibd/izy156

Systematic Review and Meta-analysis : Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. / Yung, Diana E.; Horesh, Nir; Lightner, Amy; Ben-Horin, Shomron; Eliakim, Rami; Koulaouzidis, Anastasios; Kopylov, Uri.

In: Inflammatory Bowel Diseases, Vol. 24, No. 11, 12.10.2018, p. 2327-2338.

Research output: Contribution to journalArticle

Yung, DE, Horesh, N, Lightner, A, Ben-Horin, S, Eliakim, R, Koulaouzidis, A & Kopylov, U 2018, 'Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease', Inflammatory Bowel Diseases, vol. 24, no. 11, pp. 2327-2338. https://doi.org/10.1093/ibd/izy156
Yung, Diana E. ; Horesh, Nir ; Lightner, Amy ; Ben-Horin, Shomron ; Eliakim, Rami ; Koulaouzidis, Anastasios ; Kopylov, Uri. / Systematic Review and Meta-analysis : Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. In: Inflammatory Bowel Diseases. 2018 ; Vol. 24, No. 11. pp. 2327-2338.
@article{9c8adb1e55504967ab925781ba3a8de2,
title = "Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease",
abstract = "Background: Several studies have reported the surgical outcomes of inflammatory bowel disease (IBD) patients exposed to vedolizumab (VDZ) preoperatively, with conflicting results. This meta-analysis aims to evaluate the risk of postoperative complications in IBD patients preoperatively exposed to VDZ in comparison with patients exposed to anti-tumor necrosis factor (anti-TNF) treatment or no biologic therapy.Methods: A systematic review with a meta-analysis of the existing literature was conducted. The main outcomes included the odds of developing overall postoperative complications, infectious complications, surgical site infections, need for repeat surgery, and major postoperative complications, as defined by the Clavien-Dindo criteria.Results: Four studies were included in the meta-analysis. The risk of all postoperative complications was not significantly different between IBD patients exposed preoperatively to VDZ vs anti-TNFs (odds ratio [OR], 0.64; 95{\%} confidence interval [CI], 0.21-1.88). In patients with ulcerative colitis (UC), the OR for complications was significantly lower in VDZ-exposed as opposed to anti-TNF-exposed patients (OR, 0.35; 95{\%} CI, 0.14-0.85); the comparison was insignificant in Crohn's disease. There were no significant differences in the risk of infectious complications, surgical site infections, need for reoperation, or major surgical complications in patients exposed to VDZ vs anti-TNFs. There were no significant differences in outcomes when comparing patients exposed to VDZ with those not given biologic therapy.Conclusions: This meta-analysis did not detect an increased risk of postoperative complications with preoperative VDZ exposure; the risk of overall complications may be lower in UC patients in comparison with those with anti-TNF exposure. These results merit further verification in future studies.",
author = "Yung, {Diana E.} and Nir Horesh and Amy Lightner and Shomron Ben-Horin and Rami Eliakim and Anastasios Koulaouzidis and Uri Kopylov",
year = "2018",
month = "10",
day = "12",
doi = "10.1093/ibd/izy156",
language = "English (US)",
volume = "24",
pages = "2327--2338",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Systematic Review and Meta-analysis

T2 - Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease

AU - Yung, Diana E.

AU - Horesh, Nir

AU - Lightner, Amy

AU - Ben-Horin, Shomron

AU - Eliakim, Rami

AU - Koulaouzidis, Anastasios

AU - Kopylov, Uri

PY - 2018/10/12

Y1 - 2018/10/12

N2 - Background: Several studies have reported the surgical outcomes of inflammatory bowel disease (IBD) patients exposed to vedolizumab (VDZ) preoperatively, with conflicting results. This meta-analysis aims to evaluate the risk of postoperative complications in IBD patients preoperatively exposed to VDZ in comparison with patients exposed to anti-tumor necrosis factor (anti-TNF) treatment or no biologic therapy.Methods: A systematic review with a meta-analysis of the existing literature was conducted. The main outcomes included the odds of developing overall postoperative complications, infectious complications, surgical site infections, need for repeat surgery, and major postoperative complications, as defined by the Clavien-Dindo criteria.Results: Four studies were included in the meta-analysis. The risk of all postoperative complications was not significantly different between IBD patients exposed preoperatively to VDZ vs anti-TNFs (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.21-1.88). In patients with ulcerative colitis (UC), the OR for complications was significantly lower in VDZ-exposed as opposed to anti-TNF-exposed patients (OR, 0.35; 95% CI, 0.14-0.85); the comparison was insignificant in Crohn's disease. There were no significant differences in the risk of infectious complications, surgical site infections, need for reoperation, or major surgical complications in patients exposed to VDZ vs anti-TNFs. There were no significant differences in outcomes when comparing patients exposed to VDZ with those not given biologic therapy.Conclusions: This meta-analysis did not detect an increased risk of postoperative complications with preoperative VDZ exposure; the risk of overall complications may be lower in UC patients in comparison with those with anti-TNF exposure. These results merit further verification in future studies.

AB - Background: Several studies have reported the surgical outcomes of inflammatory bowel disease (IBD) patients exposed to vedolizumab (VDZ) preoperatively, with conflicting results. This meta-analysis aims to evaluate the risk of postoperative complications in IBD patients preoperatively exposed to VDZ in comparison with patients exposed to anti-tumor necrosis factor (anti-TNF) treatment or no biologic therapy.Methods: A systematic review with a meta-analysis of the existing literature was conducted. The main outcomes included the odds of developing overall postoperative complications, infectious complications, surgical site infections, need for repeat surgery, and major postoperative complications, as defined by the Clavien-Dindo criteria.Results: Four studies were included in the meta-analysis. The risk of all postoperative complications was not significantly different between IBD patients exposed preoperatively to VDZ vs anti-TNFs (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.21-1.88). In patients with ulcerative colitis (UC), the OR for complications was significantly lower in VDZ-exposed as opposed to anti-TNF-exposed patients (OR, 0.35; 95% CI, 0.14-0.85); the comparison was insignificant in Crohn's disease. There were no significant differences in the risk of infectious complications, surgical site infections, need for reoperation, or major surgical complications in patients exposed to VDZ vs anti-TNFs. There were no significant differences in outcomes when comparing patients exposed to VDZ with those not given biologic therapy.Conclusions: This meta-analysis did not detect an increased risk of postoperative complications with preoperative VDZ exposure; the risk of overall complications may be lower in UC patients in comparison with those with anti-TNF exposure. These results merit further verification in future studies.

UR - http://www.scopus.com/inward/record.url?scp=85054893319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054893319&partnerID=8YFLogxK

U2 - 10.1093/ibd/izy156

DO - 10.1093/ibd/izy156

M3 - Article

VL - 24

SP - 2327

EP - 2338

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 11

ER -